MassChallenge

Extracellular channels biology, digitalisation and biomanufacturing expertise to accelerate developments in biotech. We use our scale up experience and our deep insights into cellular behaviour to produce biomass for cultivated meat companies more efficiently. We're digitalising process development, pulling together huge quantities of data to make better decisions faster and at scale.

Fotortec is a biotechnology company focused on sustainable protein production. It specializes in producing mushroom-based ingredients that leverage technology to convert various types of vegetable waste into fully traceable plant-based products. This innovative approach aims to provide consumers with adequate nutrition while promoting environmental sustainability. Through its processes, Fotortec contributes to reducing food waste and enhancing the availability of nutritious food options.

Sóliome is a Biotechnology company that develops protein-based sunscreens that are safe. The company was founded in 2021 and is based in San Francisco, California.

Via a combination of materials, biotechnology and optics IP, we are developing a microbiological testing solution applicable to pathogens, allergens and spoilage organisms. The core technology enables quantitative and array-based tests for high throughput, low component and overall solution cost, best in class time-to-result, and a hardware design road-map including small footprint and handheld form factors. The combination of consumables incorporating our proprietary materials and biological agents, low-cost hardware and analytics we're developing is uniquely positioned to serve the market.

CNS Therapy, they contribute to human well-being through mind-body therapy and the research, design, education, and sale of devices that alleviate chronic disease, restore health, and extend useful life. They are a spin off from the University of North Carolina (UNC). Their base technology is a patent pending approach to chronic pain which combines operant behavioral therapy with a proprietary device which enhances learning and resets the autonomic nervous system - called SET - Systolic Extinction Training. They are dedicated to providing long lasting pain relief to patients. Their unique combination of psychological training and electrostimulation helps chronic pain patients to starkly reduce or even eliminate their pain and allow them to return to their daily lives.

Econutri is a company focused on sustainable protein production through the recycling of CO₂. Utilizing advanced bio-processing technology, it transforms carbon dioxide into high-quality proteins that serve a variety of markets, including livestock feed, pet food, non-food products, and human food options. By providing eco-friendly and nutritious protein alternatives, Econutri aims to make a positive environmental impact while helping to reduce the global carbon footprint.

SCALE Advanced Biocomposites specializes in the development of natural-fiber composites aimed at advancing the use of bio-based materials across various industries, including sporting goods, automotive, wind power, and aerospace. The company's innovative materials and technologies offer an effective alternative to carbon fiber, enhancing performance while simultaneously reducing costs and greenhouse gas emissions. This approach supports clients in their efforts to decarbonize high-performance composites, contributing to a more sustainable built environment. Through its focus on creating new, bio-based materials, SCALE seeks to significantly lower emissions and promote the adoption of eco-friendly solutions in multiple sectors.

We have cracked the code. Umami is the world’s first bionic farming company specialising in growing pure food with superior taste.

At Updairy, we're harnessing the power of microorganisms to create animal-free dairy.

Yeastime's value proposition is its innovative retrofitting ultrasound technology, which accelerates fermentation by up to 30%. This groundbreaking approach not only boosts efficiency but also represents a significant leap forward in food technology, setting Yeastime apart as a true pioneer in the field.

Restoring crops' ability to defend against pests.

Producer of food products intended to provide fish meat alternatives through cell cultivation. The company specializes in producing cultivated cell-based fish fat to greatly enhance the flavor, texture aroma and nutrition of alternative protein products, enabling consumers to get healthy fats such as omega-3 that protect from heart diseases.

Sonali Bioplastics solves the plastic pollution problem with plant based alternatives that reduces carbon emissions. Sonali Bioplastics takes a sustainable development approach toward solving plastic problems and promote eco-friendly farming. The company was founded in 2019 and is based in San Jose, California.

SeaStock is a global marine research company focused on developing solutions for the production and extraction of compounds derived from seaweed and algae. The company specializes in the cultivation and processing of asparagopsis seaweed, which is utilized in methane-reducing feed ingredients. By offering a range of products, SeaStock enables clients to select the specific solutions that meet their needs. Through its innovative approach, the company aims to contribute to sustainable practices in marine science and agriculture.

LiveGrow Bio is a biotechnology company specializing in microbial fermentation and formulation. It has developed a patented technology that significantly reduces the production cost of biopesticides and biostimulants by up to 95%, while also extending their shelf life to over two years at room temperature. This innovation facilitates the commercialization of biological products, making them viable solutions for a wide range of crops, beyond just high-value organic ones. LiveGrow's technology allows for the modular production of any microbe as a biostimulant or biopesticide, utilizing a unique manufacturing method that grows microbes directly inside retail packaging sold to farmers. This approach eliminates the need for traditional large-scale fermentation facilities and the associated processing steps, enhancing scalability and efficiency in the agriculture sector.

Azul Bio offers technology to preserve and restore marine ecosystems and expand the productivity of marine industries at scale.ensure coral reefs continue serving as a foundation to our oceans by increasing their resiliency against climate change.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

Narval develops synthetic antibody mimetic proteins (AMP) to replace conventional antibodies on novel first-in-class immunotherapeutics, making them as affordable, flexible and easy to use as small molecule drugs. AMPs are 40 times smaller than a monoclonal antibody but with the same biological function. Our AMP can penetrate tissue barriers, generate limited immune reactions, can target very small and hard-to-reach antigens, and are heat resistant. These advantages gives our AMP technology the ability to develop immunotherapeutic drugs for disease applications that have been previously impossible to develop because of monoclonal antibody limitations. Our AMPs can be used to generate novel first-in-class antibody drugs to treat, for example, respiratory diseases with inhaled antibodies, eye diseases with non-invasive antibodies on eye drops or autoimmune and skin diseases with antibodies in transdermal controlled release patches.

Astron Medtech is a medical technology company focused on improving patient outcomes in tendon repair. The company develops disposable minimally invasive surgical devices that significantly reduce recovery time from six months to four months. By utilizing less invasive and sustainable surgical techniques, Astron Medtech aims to enhance the efficiency of surgical services while providing better options for patients undergoing tendon repair procedures.

KardioStatus specializes in transforming biometric data into actionable therapeutics. The KardioStatus platform has a wide range of features created by premiere physicians and engineers to develop a patient's unique biometric profile and provide personalized clinical therapeutics.

Form Biologics is a new platform technology for the injectable formulation of biologic medicines in order to make treatments more patient-friendly and efficacious.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

AI startup that provides treatment personalization using patients' tumor samples

Stellate Therapeutics is a private biotechnology company specializing in the development of small molecules derived from human gut bacteria to create personalized therapies for neurological diseases. The company focuses on addressing age-related neurological conditions, particularly through its research on the gut-brain axis. Stellate has developed a portfolio of drug candidates, including AMA-101, which aims to be a first-in-class therapy for Parkinson's disease. Through its microbiome-derived medicine platform, Stellate Therapeutics is engaged in comprehensive research and has established capabilities in discovery, screening, production, and diagnostic development, striving to provide effective treatments for neurological disorders.

Earnest Agriculture collaborates with farmers to transform agricultural waste into innovative biofertilizers that enhance crop yields. By converting waste products such as manure and vegetable remnants, the company provides an eco-friendly solution that not only helps farmers manage their waste but also offers them a potential source of additional income. Utilizing a combination of composting, vermicomposting, and advanced microbial technologies, Earnest Agriculture develops proprietary fertilizers designed to improve soil quality, promote drought resistance, and suppress pathogens. This approach not only reduces the environmental impact of farming but also allows farmers to lower their input costs while increasing their productivity.

Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecology clinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Cultimate Foods is a cellular agriculture company focused on developing cultivated fat for hybrid alt-meat products. By replicating the structure of animal fat tissue, the company aims to create plant-based fat alternatives that enhance the sensory experience of meat consumption. Utilizing a unique technological approach to 3D cultivation, Cultimate efficiently produces its ingredients while reducing production costs. The company’s innovative methods enable the development of cell-cultured meat alternatives that provide a sustainable and ethical option for consumers seeking to enjoy meat without compromising on taste or texture.

Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

miniMarrow presents a new disruptive therapeutic approach for the in-situ production of blood components in leukemic patients to replace weekly and burdensome transfusions markedly increasing patient quality-of-life. miniMarrow is operating in stealth mode. miniMarrow was established in Renens, Vaud

Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.

Ostiio is focused on developing an innovative bone distraction system aimed at correcting skeletal deformities and deficiencies. The company has created a fully implantable device that is buried beneath the patient's skin, eliminating the need for external components. This advanced system features a magnetically driven distraction mechanism that can be expanded with precision and monitored remotely by physicians. This programmability provides surgeons with enhanced transparency and control during the treatment process, addressing a longstanding challenge in skeletal correction. Ostiio operates as a company under the Penn Center for Innovation, emphasizing its commitment to advancing medical technology in orthopedics.

Selmod, based in Basel, Switzerland, specializes in developing innovative therapies aimed at treating life-threatening, multi-drug resistant infections. The company focuses on discovering and advancing small molecules and peptides that target new mechanisms of action, addressing the urgent need for effective treatments in hospital settings where first-line therapies have failed. Selmod aims to provide second-line and last-resort options through a disruptive approach that incorporates dual modes of action to overcome resistance mechanisms. The company's lead candidates, SLM500, SLM100, and SLM300, have shown promise in preclinical studies, with market projections indicating a total available market exceeding $9 billion. With an experienced leadership team skilled in advancing clinical candidates for major pharmaceutical companies, Selmod plans to utilize funding to advance three IND-enabling candidates and six lead-optimized candidates into proof-of-concept stages.

INIA Biosciences focuses on creating non-invasive medical devices that leverage sound wave technology to manage chronic inflammatory diseases. The company's innovative system combines biomarker monitoring with an ultrasound stimulator, aimed at reducing inflammation associated with transplant rejection and decreasing reliance on immunosuppressant medications. This home-administered, closed-loop monitoring system provides physicians with advanced diagnostic capabilities to improve the treatment and prevention of organ failure, ultimately enhancing patient care in chronic disease management.

BioBQ is a cultivated meat company focused on producing slaughter-free beef brisket and other BBQ meats from cultured animal cells. Utilizing proprietary technologies, the company efficiently creates whole cuts of meat in weeks, significantly reducing the time compared to traditional cattle farming. This innovative approach not only allows for precise control of meat content and flavor but also minimizes the environmental impact associated with conventional meat production. By offering a sustainable alternative, BioBQ aims to meet the growing consumer demand for tasty and environmentally friendly meat options, ensuring that animal welfare and climate concerns are addressed.

Netnoids Rx Laboratories operates a cancer contract research organization that uses patient-derived organoid model systems to help find a cure for rare cancers.

Ronawk is a biotechnology company that specializes in the development of T-Block technology, which produces patient-specific biologics for the treatment of diseases, including cancer, organ injuries, and burns. The company has created a proprietary method for growing primary stem cells in a three-dimensional environment, allowing these cells to retain their essential characteristics outside the body. This innovative approach enables the rapid expansion of stem cells, making them suitable for early-stage diagnostics and the repair of injured tissues. Additionally, Ronawk focuses on preserving primary cells from patients for future use in reconstructive surgeries, thereby enhancing the efficiency and density of human cell growth for tissue generation and disease modeling.

Algdeha is a provider of sustainable biotechnology solutions to fish-based product-dependent industries. It develops sustainable production methods to produce algae on an industrial scale with low cost to use as animal feed for replacing animal-based products. Its innovative production methods allow us to produce algae with lower costs by using wave energy, sunlight, heat from the environment.

Condor Software specializes in clinical finance software designed to enhance financial decision-making in the pharmaceutical and biotech sectors. By integrating real-time clinical trial data and facilitating collaboration with third-party vendors, the company enables more accurate accounting and financial planning for clinical programs. Its software promotes operational efficiency by streamlining workflows and reducing the time spent on cash flow management. The focus is on optimizing financial resources to accelerate the development of innovative treatments, thus supporting companies in making informed business decisions that drive impactful outcomes.

Galileo Innovations develops human performance-optimizing biotech gear and equipment for athletes, first responders, military members, and labor industry workers. Its proposed technology, KordoFan, augments users with actionable insights concerning environmental and biometric hazards in real-time to target heat injuries; through an array of biomimicry cooling designs, the device aids in speed, agility, mental clarity, muscle recovery, strength, and stamina during training/shifts.

AMF Medical is focused on developing Sigi, an innovative patch pump designed to administer insulin with exceptional ease of use. This novel device is intended for seamless integration into closed loop systems, compatible with third-party Continuous Glucose Monitoring products and dose-calculating algorithms. The company's mission is to alleviate the therapy burden faced by individuals with diabetes, ultimately aiming to enhance their quality of life. AMF Medical was established in early 2021 as a spin-off from Advanced Microfluidics, which specializes in high-end lab equipment components that utilize related technologies.

LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

We create healthy and sustainable solutions for the world based on insects. A very nutritive and eco friendly food source. Currently we are using about 50% of the habitable land for agriculture and the livestock industry is the major contributor to CO2 emisions, but In just 30 years the amount of food available will not be enough for the world`s population. By making healthy, and tasty products from insect powder such as flour for bread, cake mix, and even protein shakes, we are able to reduce the amount of livestock usage and also provide a sustainable and scalable solution. Our business model is based on 3 keypoints: >Mass and Standarized Production which is possible using our insect incubator (which is patent pending) >Sustainable and efficient Production since Costa Rica has the perfect weather conditions, >And our Partner Program to provide jobs and income to the poorest sectors of Costa Rican society. Our partner program is supported by BID Lab and Fundecooperación who are helping us deliver the program on a national scale. Costa Rica Insect Company and we Save the World Eating Bugs!

Labinnova detects Breast Cancer in a Breath Sample with 98% sensibility. providing Qualitative results.

GreenBTS specializes in developing high-technology and sustainable products aimed at enhancing agricultural efficiency and environmental responsibility. The company manufactures organic biofertilizers and biopesticides designed to improve urban farming, plant care, and food production. These products protect crops from pests and diseases while offering specially formulated nutrients tailored to various crop types, which contribute to better growth and quality. By focusing on innovative and eco-friendly solutions, GreenBTS enables farmers to safeguard their crops until harvest, promoting a more sustainable approach to agriculture.

Uniphage is a biotech company that eliminates bacterial infections by combining the power of bacteriophages with artificial intelligence. Their first target disease is citrus greening, an incurable and debilitating disease that costs the United States more than $2 billion each year. Uniphage created the first commercially effective models for computationally predicting safe bacterial viruses against target bacterial infections, as well as discovered a variety of targets. This enables them to deliver new antimicrobial, safe, and precise products to market much more quickly.

Therapeutic Vision focuses on the development of pharmaceuticals primarily for the companion animal market and eventually their owners.

BioSens8 is a developer of advanced biosensors designed to enhance health monitoring and prevent chronic diseases. The company's innovative platform offers real-time, quantitative biosensors that serve various applications. In healthcare, these biosensors assist women in assessing their fertility health, providing crucial information for family planning. In agriculture, BioSens8's technology enables farmers to manage herds effectively and optimize animal reproduction. Additionally, the biosensors can evaluate environmental health, contributing to the revitalization of fragile ecosystems. By catering to the healthcare, agriculture, military, and biomanufacturing sectors, BioSens8 aims to provide efficient solutions for holistic health monitoring.

AcousticaBio is focused on transforming intravenous medications into formulations suitable for subcutaneous injection. The company has developed a fluid processing technology that creates complex microparticles necessary for these subcutaneous formulations. This innovative approach allows for the conversion of intravenously delivered biologic products into highly concentrated, small-volume injections. By enabling patients to self-administer life-saving drugs with reduced pain and discomfort, AcousticaBio aims to streamline treatment processes, minimizing the need for lengthy hospital visits and enhancing patient convenience.

Akttyva Therapeutics specializes in the development of targeted therapeutics aimed at addressing cell barrier dysfunction associated with various vascular disorders. The company leverages a deep understanding of biological pathways, along with advanced artificial intelligence and machine learning techniques, to design solutions that enhance the treatment of these conditions. Through its innovative approach, Akttyva Therapeutics seeks to provide healthcare professionals with effective tools to manage and treat disorders related to cell barriers.

Gensor develops a virus testing platform based on the gene field-effect transistor technology.

Stemloop is a biotechnology company focused on developing innovative cell-free biosensing products that enhance chemical and molecular testing processes. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates accessible and actionable biosensors that are faster, cheaper, and easier to use than traditional laboratory tests. The company's mission is to address unmet needs in chemical sensing and detection, enabling medical professionals to deliver accurate and timely test results at reduced costs. Through its novel technology, Stemloop aims to unlock the potential of biology to respond effectively to various global challenges.

MycoNourish customizes microbes to suit specific crops and solve targeted problems in their production – enhancing yields and adding value for growers.

Sophie's BioNutrients is developing a new sustainable plant-based protein out of microalgae using fermentation technologies.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

FairFlavor develops nutritious vegan alternative dairy food made of a super nut from Indonesia using a patented fermentation technology

Vectech is a public benefit corporation based in Baltimore, MD, specializing in an AI-based diagnostic system for medical entomology. The company has developed an identification system that accurately determines species, sex, and other essential characteristics of mosquito and tick populations. This technology is currently deployed in seven countries and serves various clients, including municipal and national public health programs, NGOs, and malaria control initiatives. By providing tools that reduce labor costs associated with mosquito surveillance, Vectech empowers researchers and public health organizations to detect threats from mosquito-borne diseases like dengue and malaria, facilitating early intervention and customized responses to potential outbreaks.

Fybraworks Foods, Inc. is a food biotechnology company founded in 2020 and based in Minnetonka, Minnesota. It specializes in developing alternative meat substitutes and animal-free meat structural proteins through advanced fermentation techniques. The company aims to replicate the taste and texture of traditional meat while promoting sustainability and humane practices. By providing innovative technological solutions, Fybraworks Foods enables industry leaders and consumers to access meat alternatives that minimize animal slaughter and reduce greenhouse gas emissions, thereby contributing to environmental preservation.

ClearLeaf specializes in developing non-toxic fungicides and bactericides for agricultural applications, utilizing patent-pending technology that is organic certified in the EU and Japan. The company offers pre and post-harvest solutions for a variety of crops, including coffee, bananas, pineapples, and various vegetables. Its flagship product, GotaBlanca®, is currently marketed in Costa Rica, with plans to expand into Central America. ClearLeaf has established an exclusive commercial agreement with Colono Agropecuario, the largest agrochemical distributor in the region, which has significantly boosted its sales since the partnership began in 2021. The company's mission is to provide sustainable alternatives to toxic agrochemicals, enhancing farm efficiency while safeguarding human health and the environment, ultimately improving safety conditions for agricultural workers.

BioEclosion seeks to enhance user-friendly quantitative diagnostics to new molecular biomarkers for fast identification of emerging diseases that affect global health. The company started its activity with several patents, the most important being Celifast: a non-invasive approach for the detection of celiac disease. Addressing point of care attention of patients, the core technology has been successfully validated and the team is currently working on further development for commercialization.

BestHealth4U focuses on the research and development of advanced solutions for manufacturers of class 1 medical devices. The company specializes in medical adhesive technologies that aim to prevent skin injuries, accelerate healing, and enhance overall patient health. Its innovative and environmentally friendly adhesive products are designed to safeguard patients from skin damage, discomfort, irritation, and infections by improving the attachment of bandages, dressings, and medical devices to the skin. By providing effective solutions, BestHealth4U assists healthcare providers in reducing medical adhesive-related skin injuries and promoting the well-being of patients.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi through a fermentation process. Founded in 2019 and based in both San Francisco, California, and Rosario, Argentina, Michroma aims to replace synthetic pigments and those sourced from animals and plants with sustainable, naturally produced alternatives. The company harnesses synthetic biology to develop proprietary fungal strains that generate high-performance ingredients in bioreactors. Currently, Michroma is prototyping its innovative pH-stable and heat-stable food colorants in collaboration with leading food and beverage and cosmetic companies. Additionally, the company is exploring the production of mycoprotein and other ingredients, making strides in the sustainable ingredients market.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

Digi.Bio is a Netherlands-based company that specializes in developing software solutions for the healthcare industry, particularly in the field of cell therapies. It offers a microfluidic platform that automates repetitive and manual laboratory workflows, utilizing artificial intelligence and electrowetting technology to manipulate droplets at a microscale. This innovative approach aims to streamline multistep liquid handling applications, replacing traditional pipetting methods. Digi.Bio's platform delivers comprehensive analysis of cell therapies, evaluating their performance and outcomes at the single-cell level within 24 hours, while minimizing material waste. By enhancing automation in medical and pharmaceutical settings, Digi.Bio supports the advancement of bioengineering processes.

Green and Seed Corporation innovates rice farming by growing rice outside of the water without sacrificing yield by using the weeding and moisturizing functions of biodegradable films.

Microbe Plus developed innovative microbiological bio-products that combine biological products and molecular biology. Our bioproducts - probiotics for plants are multi-strain, thanks to which they provide comprehensive plant protection against a wide spectrum of plant pathogens. Our mission is to create efficient and inexpensive bioproducts to protect and stimulate plant growth crops, orchards, flowers, and ornamental plants.

Ittinsect is the biotech startup that developed the sustainable alternative to aquaculture feed. Ittinsect produces high performance feeds through the microbiological treatment of novel raw ingredients including insects, microalgae and agricultural by-products, in line with the circular economy principles. With Ittinsect, there is no longer need to catch fish from the marine environment as nutrition for farmed fish. The company’s mission is making aquaculture ocean-impact neutral.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

FermBiotics is a microbiome company on a mission to improve gut health all over the world. FermBiotics produce sustainable, fermented plant ingredients for food.

Frankles is a climate technology startup focused on transforming the ingredient production landscape by eliminating petroleum extraction. The company has developed NoDex, an innovative platform that utilizes machine learning and molecular data to design extraction processes from plant raw materials and agro-industrial waste. This technology enables the creation of high-value sustainable ingredients, such as flavorings, functional compounds, antioxidants, and biocompounds. By providing sustainable extraction methodologies, Frankles aims to support the beverage industry in transitioning to green ingredients, contributing to the broader goal of achieving net zero emissions by 2050. Through its scalable solutions, Frankles envisions a decentralized and environmentally friendly approach to ingredient production.

TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

Kinoko is growing the next generation of superfoods. We are using the power of fungi and deep-tech fermentation to grow delicious and highly nutritional food in a sustainable way.

Matricelf is a biotechnology company focused on the development of advanced tissue and organ engineering solutions. Established in 2019 by Professor Tal Dvir from Tel Aviv University, the company utilizes a proprietary decellularization process to extract stromal cells and extracellular matrix (ECM) from small omental biopsy samples. This process produces a thermo-responsive hydrogel that incorporates reprogrammed induced pluripotent stem cells (iPSCs), which are differentiated into functional tissues using a patent-pending methodology. Matricelf's innovative approach aims to reduce the risk of implant rejection and includes the production of spinal cord implants designed for patients with traumatic spinal cord injuries. These implants help restore neuronal activity and motor functions, enabling patients to reintegrate into their communities and improve their daily lives. The company is committed to advancing medical treatments through its platform for autologous matrix and cell implants, addressing a wide range of medical conditions.

Liposphere develops and manufactures AqueousTech, an innovative water-based platform technology that offers advanced lubricants for various medical and technological applications. This IP-protected technology creates a durable protective boundary layer on both biological and synthetic surfaces, effectively resisting high loads and pressures. AqueousTech is significantly more effective than traditional oil- and hyaluronic-based substances, and it is biocompatible. The company's flagship product, AqueousJoint, is designed as a local injectable treatment for knee osteoarthritis. Additionally, Liposphere's technology utilizes hydration water as the key lubricating element, allowing for efficient coating of surfaces and enabling the encapsulation and targeted delivery of active pharmaceutical ingredients or supplements.

EcoPhage is a biotechnology company focused on developing and commercializing bacteriophage-based solutions for crop protection, specifically targeting bacterial plant diseases. With an estimated 10% of global food production lost annually due to these diseases, EcoPhage's innovative products leverage the unique properties of bacteriophages—viruses that specifically target bacteria—to provide effective and environmentally friendly alternatives to traditional pesticides. The company's proprietary platform, co-developed with the Weizmann Institute of Science, utilizes advanced screening and characterization methodologies to identify the most promising bacteriophage candidates. By offering nontoxic solutions that enhance plant yield and promote sustainability, EcoPhage aims to revolutionize the agricultural sector by reducing disease-related losses and transforming the bactericides market into a safer and more sustainable framework. Through its commitment to combating plant diseases, EcoPhage is poised to contribute significantly to the future of agriculture.

ReelData provides a suite of artificial intelligence and automation products that allow land-based fish farms to increase production volumes while decreasing risk and wasted resources. It also provides reliable, accurate monitoring, analysis, and optimized automation working with each farm 1-on-1 to increase operational efficiency, save costs, grow fish faster, and reduce risks.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

Path Ex, Inc. is a Nashville-based company established in 2017 that specializes in the development of extracorporeal blood-cleansing equipment aimed at treating sepsis, a severe and often fatal condition linked to blood-borne infections. The company has created a proprietary technology that selectively separates and captures bacteria and toxins from human blood, offering a novel approach to treatment. Unlike traditional methods that rely on broad-spectrum antibiotics to kill infections, Path Ex's device effectively removes intact bacteria from the bloodstream, regardless of the bacteria type or antibiotic resistance. This innovative technology has the potential to improve patient outcomes by reducing diagnostic times, treatment costs, readmission rates, and fatalities associated with sepsis.

Tremedics develops bioresorbable technology for congenital heart disease patients with congenital heart disease need devices that resorb within their bodies as they grow. Their technology utilises a minimally invasive surgery procedure for stent delivery and permits vessel growth as the stent resorbs in the body.

Onexio Biosystems is a research and development company. They offer HTS screens that typically utilize a single reporter cell type that lacks important confounding biology, including drug metabolism and paracrine and endocrine cell interactions. Their microDUO supports co-culture and multi-culture to improve human relevance in drug discovery and chemical screening.

Scrufy is a vital element of every ship, performing hull grooming and autonomous, ongoing monitoring. It keeps track of biofouling and deals with it at the cellular level. There is no need for collection and disposal, and thus there is no threat from invasive species or from the discharge of biocides from the coating.

Amphasys is a technology company focused on its activities in developing and marketing a novel, chip-based single cell analysis technology. Its aim is to simplify, speed up, and miniaturize complex cell analyses and move them to the point-of-use, which may be outside well-equipped research and analytical laboratories. The company’s basic technology has been developed in 2004 in collaboration with the Swiss Federal Institute of Technology Lausanne. Consequently, several years of research with different cell types proved that the technology is suitable for a wide array of applications. It is currently being used in the analysis of pollen and milk. In 2013 Amphasys was awarded with the most prestigious Swiss startup price by the W.A. de Vigier Foundation. It was also supported by the Albert Koechlin Foundation and certified by CTI Invest. Amphasys was founded in 2012 as a spin-off from Axetris AG, a company of the Leister group.

O2 RegenTech is focused on developing innovative wound care solutions that are both cost-effective and user-friendly. Utilizing proprietary biopolymer technology, the company's flagship product, OXAID™, serves as an oxygenating, moist, and antimicrobial dressing designed to enhance and accelerate the healing of chronic wounds. By addressing the need for effective wound management, O2 RegenTech aims to provide accessible options for individuals suffering from chronic conditions, ultimately improving patient outcomes and quality of life.

Sano Chemicals is an early-stage biotechnology company focused on developing innovative anti-infectives for both clinical and agricultural applications. The company aims to enhance health and promote a sustainable environment through its unique products. Sano Chemicals specializes in antifungal treatments, particularly targeting fungal infections in humans as well as bio-control methods for crops. One of their key compounds, occidiofungin, is a novel antifungal discovered by researchers at Mississippi State University and Texas A&M University. The company is working on various applications of occidiofungin to address fungal infections affecting nails, skin, and systemic health, while also developing solutions to combat fungal diseases in plants. Through these efforts, Sano Chemicals seeks to revolutionize the antifungal industry and improve quality of life for patients and sustainable agricultural practices.

MIBIOMICS mission is to develop innovative, safe, and effective microbiome-based solutions to treat currently incurable skin diseases.

Parx Materials recognized a growing demand for plastics with antibacterial/antimicrobial properties and from their expertise they knew that the available solutions to achieve such materials were not suitable for large-scale application/adoption because of their possible harmful effects on humans, animals or the environment as a whole. They had foreseen the dangers, insecurities and disadvantages of these solutions. Over four years of dedicated biomimetic research has been invested to create a 100% safe and biocompatible technology to inhibit the growth of bacteria on the surface of plastic with the use of a Biomimetic approach in the design and engineering of the materials. The discoveries and inventions done during this research are truly unique and groundbreaking. A team of 11 professors, scientists and researchers with decades of experience in the field of Nano- and biotechnologies and skilled in chemical analyses and chemical-physical and microbial analyses have been working together with a renown European university for chemistry. The result is a worldwide patent-pending innovation for highly effective plastics with an antibacterial/antimicrobial effectiveness rate of 98-99% measured according to ISO 22196 and most of all: safe. Parx Plastics Sanipolymers are safe for humans, safe for animals and safe for the environment.

ChondroNest is developing the application of this intellectual property for the reconstruction of Hyaline cartilage. They are aiming to conduct preclinical tests on animal models for two indications, the Osteochondritis and subsequently the Osteoarthrosis. After the first in-man preclinical trials the product will be licensed to major MedTech companies for sales and marketing while they will retain the production of ChondroNest™ pastes.

Enzymit is focused on transforming global manufacturing by advancing cell-free bio-production technology, which aims to reduce reliance on scarce resources and enhance sustainability. The company develops novel enzymes using artificial intelligence and deep learning algorithms, enabling the creation of innovative molecular machines that can convert abundant feedstocks into valuable products across various sectors, including pharmaceuticals, cosmetics, food, and materials. By employing small, modular bio-reactors, Enzymit enhances efficiency, reduces costs, and minimizes environmental impact compared to traditional whole-cell bio-production methods. This approach not only fosters resource independence but also allows for greater flexibility in product customization, positioning Enzymit as a competitive alternative to conventional chemical manufacturing.

Applied Bioplastics is dedicated to reducing reliance on petroleum-based plastics by offering affordable, high-grade recycled alternatives made from sustainable plant materials sourced from developing nations. The company's bioplastic products aim to diminish petroleum dependency, lower carbon dioxide emissions, and mitigate habitat destruction. By combining plant fibers with recycled or biobased polymers, Applied Bioplastics creates materials that can be easily molded or extruded for use in various industries, including household goods, automotive, appliances, electronics, and outdoor equipment. This approach not only addresses the economic barriers that prevent companies from adopting recycled plastics but also allows them to utilize carbon-negative plant materials as substitutes for traditional petrochemical feedstock without compromising quality or profit margins.

Thinks Works is an early-stage biomedical company developing ideas and products that help to solve problems that humans are dealing with. It is the concept of founder Ryan C. Murdock, MD. Through his interactions with his patients dealing with the condition of scoliosis, he saw a need for improvement in the treatment of scoliosis. He set this as a goal and now has begun to build an incredible team to bring his vision to reality so that we may dramatically improve the lives of these patients. Its device is for the non-operative treatment of adolescent scoliosis, a severe curvature of the spine in kids. Approximately 10,000 US kids per year require brace treatment. The current treatment is a custom-made hard plastic brace. It keeps the spine immobile by compressing the ribs. It has poor patient compliance and outcomes at a high patient cost. Its novel device will improve patient comfort, compliance, and outcomes at a lower total patient cost.

Biomineral Systems focuses on environmental biochemical research and technology, offering a range of services aimed at tackling global environmental challenges. The company provides expertise in phosphorus management, soil organic carbon management, and soil quality enhancement. It also specializes in biogeochemical modeling for forest management, carbon trading and capture, mineral synthesis and characterization, and acid mine drainage solutions. By serving as environmental policy advisors to government entities and medium to large businesses, Biomineral Systems supports efforts to improve food security, promote environmental sustainability, and enhance biodiversity. Additionally, they develop and distribute decision-support tools that assist scientists and engineers in addressing complex environmental issues.

EM Device is a biotechnology company focused on developing an innovative abscess drainage tool that aims to simplify the treatment of abscesses. This device allows healthcare providers to bypass the traditional incision and drainage approach, which is often lengthy and uncomfortable for patients. By utilizing this new tool, the company significantly reduces the procedure failure rate by 50%, eliminates the necessity for follow-up visits, and enhances overall treatment outcomes. Additionally, the device shortens the time required by healthcare providers, minimizes patient discomfort, and lowers associated costs, thus improving the efficiency and effectiveness of abscess management.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

KriyaBio specializes in developing innovative drug delivery solutions centered on its proprietary permeation enhancer, KB01. This advanced technology functions as a tight junction modulator, significantly improving the absorption of co-administered therapies. KriyaBio aims to replace traditional intravitreal injections of biologics with eye drops, promoting greater patient safety and compliance while reducing overall healthcare costs. Through its novel approach, the company addresses key challenges in drug delivery, enhancing the efficacy and convenience of therapeutic treatments.

TZOFEN biological therapeutics are developing a novel biological platform for the treatment of various cancer types.

Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry.

Ouli is a skincare manufacturing company s[ecializes in regenerating axolotl salamander and synthetic biology to extract.

Agrorobotica specializes in precision agriculture and farming management systems focused on the monitoring of parasitic insects. The company designs and provides pest traps that can be installed in fields to photograph, recognize, and count harmful insects. These traps transmit real-time results to farmers via smartphone and website, allowing them to effectively monitor the health and status of their crops. By integrating this technology, Agrorobotica enables farmers to enhance their pest management strategies and improve overall farm control.

Microbial Pulse Diagnostics is developing and deploying an innovative NIST technology for the rapid measurement of antimicrobial susceptibility. This technology “takes the pulse” of bacterial cells, sensing changes in their metabolism, motility, and growth after exposure to an effective antibiotic.